PT98944A - Processo de preparacao de anticorpos alterados e de composicoes farmaceuticas para a prevencao e tratamento de infeccoes - Google Patents

Processo de preparacao de anticorpos alterados e de composicoes farmaceuticas para a prevencao e tratamento de infeccoes

Info

Publication number
PT98944A
PT98944A PT98944A PT9894491A PT98944A PT 98944 A PT98944 A PT 98944A PT 98944 A PT98944 A PT 98944A PT 9894491 A PT9894491 A PT 9894491A PT 98944 A PT98944 A PT 98944A
Authority
PT
Portugal
Prior art keywords
infections
prevention
preparation
treatment
pharmaceutical compositions
Prior art date
Application number
PT98944A
Other languages
English (en)
Other versions
PT98944B (pt
Inventor
William J Harris
Philip R Tempest
Geraldine Taylor
Original Assignee
Scotgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotgen Ltd filed Critical Scotgen Ltd
Publication of PT98944A publication Critical patent/PT98944A/pt
Publication of PT98944B publication Critical patent/PT98944B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT98944A 1990-09-11 1991-09-11 Processo de preparacao de anticorpos alterados e de composicoes farmaceuticas para a prevencao e tratamento de infeccoes PT98944B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909019812A GB9019812D0 (en) 1990-09-11 1990-09-11 Novel antibodies for treatment and prevention of infection in animals and man

Publications (2)

Publication Number Publication Date
PT98944A true PT98944A (pt) 1992-08-31
PT98944B PT98944B (pt) 1999-02-26

Family

ID=10682003

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98944A PT98944B (pt) 1990-09-11 1991-09-11 Processo de preparacao de anticorpos alterados e de composicoes farmaceuticas para a prevencao e tratamento de infeccoes

Country Status (12)

Country Link
EP (1) EP0548190A1 (pt)
JP (1) JPH06501152A (pt)
KR (1) KR930702519A (pt)
AU (1) AU654827B2 (pt)
CA (1) CA2091335A1 (pt)
GB (1) GB9019812D0 (pt)
IE (1) IE913177A1 (pt)
MX (1) MX9101046A (pt)
NZ (1) NZ239728A (pt)
PT (1) PT98944B (pt)
WO (1) WO1992004381A1 (pt)
ZA (1) ZA917170B (pt)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
WO1992001473A1 (en) * 1990-07-19 1992-02-06 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Improved immunotherapeutic method of preventing or treating viral respiratory tract disease
US5994510A (en) * 1990-12-21 1999-11-30 Celltech Therapeutics Limited Recombinant antibodies specific for TNFα
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5646253A (en) * 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
GB9207479D0 (en) * 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
DE69332643T2 (de) * 1992-09-16 2003-11-27 The Scripps Research Institute, La Jolla Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialvirus
US6685942B1 (en) 1993-12-10 2004-02-03 The Scripps Research Institute Human neutralizing monoclonal antibodies to respiratory syncytial virus
DE69419721T2 (de) 1993-01-12 2000-04-27 Biogen, Inc. Rekombinante anti-vla4 antikörpermoleküle
CA2167835A1 (en) * 1993-07-30 1995-02-09 Richard A. Weltzin Monoclonal iga antibody against respiratory syncytial virus
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US6310185B1 (en) * 1994-03-08 2001-10-30 Memorial Sloan Kettering Cancer Center Recombinant human anti-Lewis Y antibodies
WO1995031546A1 (en) * 1994-04-28 1995-11-23 Scotgen Biopharmaceuticals, Inc. Recombinant human anti-varicella zoster virus antibodies
DE69609188T2 (de) 1995-09-18 2000-12-21 Intracel Corp., Issaquah Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
CA2257357C (en) 1996-06-07 2010-04-13 Neorx Corporation Humanized antibodies with modified glycosylation
DK0970206T3 (da) 1997-01-27 2008-10-13 Ludwig Inst Cancer Res Lage-1-tumorassocierede nukleinsyrer
ES2239801T3 (es) 1997-04-02 2005-10-01 The Brigham And Women's Hospital, Inc. Uso de un agente para disminuir el riesgo de enfermedad cardiovascular.
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
DE69939553D1 (de) 1998-12-30 2008-10-23 Beth Israel Hospital Charakterisierung der proteinfamilie von soc/crac kalziumkanälen
US7166573B1 (en) 1999-05-28 2007-01-23 Ludwig Institute For Cancer Research Breast, gastric and prostate cancer associated antigens and uses therefor
EP1218538A2 (en) 1999-06-30 2002-07-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
DK1207905T3 (da) 1999-09-03 2011-01-03 Brigham & Womens Hospital Fremgangsmåder og sammensætninger til behandling af inflammatorisk sygdom under anvendelse af cadherin-II modulerende midler
CN1402782A (zh) 1999-10-19 2003-03-12 路德维哥癌症研究院 Mage－a12抗原肽及其应用
CA2384326A1 (en) * 1999-12-23 2001-06-28 Johnson Lau Compositions and methods for l-nucleosides, l-nucleotides, and their analogs
EP1296714B1 (en) 2000-06-22 2009-08-26 University Of Iowa Research Foundation Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
DE10211088A1 (de) 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DK3072978T3 (en) 2002-05-09 2018-09-17 Brigham & Womens Hospital Inc : 1L1RL-1 AS A CARDIOVASCULAR DISEASE MARKER
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CA2515708A1 (en) 2003-02-11 2004-08-26 Transkaryotic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
EP2384753B1 (en) 2003-08-29 2016-01-06 The Brigham and Women's Hospital, Inc. Hydantoin derivatives as inhibitors of cellular necrosis
DE10341812A1 (de) 2003-09-10 2005-04-07 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10344799A1 (de) 2003-09-26 2005-04-14 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP2927693A1 (en) 2004-10-06 2015-10-07 The Brigham and Women's Hospital Relevance of achieved levels of markers of systemic inflammation following treatment
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1795596A1 (en) 2005-12-08 2007-06-13 Ganymed Pharmaceuticals AG Composition and methods for therapy and diagnosis of cancer
DE102005059242A1 (de) 2005-12-12 2007-06-14 Johannes Gutenberg-Universität Mainz, Vertreten Durch Den Präsidenten Molekulare Marker für eine Tumordiagnose und -therapie
AU2007239679B2 (en) 2006-04-13 2012-10-11 Chugai Seiyaku Kabushiki Kaisha Taurine transporter gene
EP1911851A1 (en) 2006-10-12 2008-04-16 Ganymed Pharmaceuticals AG Compositions and methods for therapy and diagnosis of cancer and cancer metastasis
EP2118141B1 (en) 2007-02-23 2014-07-30 The United States of America, as represented by the Secretary, Department of Health and Human Services Monoclonal antibodies that neutralize anthrax toxins
JP5635260B2 (ja) 2007-03-15 2014-12-03 中外製薬株式会社 ポリペプチドの製造方法
KR101577839B1 (ko) 2007-08-07 2015-12-15 추가이 세이야쿠 가부시키가이샤 이종 단백질의 제조 방법
WO2009051109A1 (ja) 2007-10-15 2009-04-23 Chugai Seiyaku Kabushiki Kaisha 異種タンパク質を高生産する細胞の作製方法
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
ES2548294T3 (es) * 2007-10-24 2015-10-15 Chugai Seiyaku Kabushiki Kaisha Célula para su uso en la producción de proteína exógena, y procedimiento de producción usando la célula
EP2108701A1 (en) 2008-04-10 2009-10-14 Ganymed Pharmaceuticals AG Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing
CN102159243B (zh) * 2008-07-21 2015-08-19 免疫医疗公司 用于改良的治疗特征的抗体的结构变体
SMT202300421T1 (it) 2009-02-20 2024-01-10 Astellas Pharma Inc Metodi e composizioni per la diagnosi e il trattamento del cancro
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
EP2221375A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
EP2423309B1 (en) 2009-04-22 2018-01-03 Chugai Seiyaku Kabushiki Kaisha A method for producing a cell capable of high-yield production of heteroproteins
EP2249159A1 (en) 2009-04-29 2010-11-10 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
DK3305813T3 (da) 2009-11-11 2020-04-20 Astellas Pharma Inc Antistoffer, der er specifikke for claudin 6 (cldn6)
HRP20171045T1 (hr) 2010-04-16 2017-10-06 Biogen Ma Inc. Protutijela anti-vla-4
US20130052209A1 (en) * 2010-04-23 2013-02-28 Purdue Research Foundation Protein drug formulations and packages
KR20190000385A (ko) 2010-05-04 2019-01-02 더 브리검 앤드 우먼즈 하스피털, 인크. 섬유증의 검출 및 치료
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
ES2989943T3 (es) 2011-05-13 2024-11-28 Astellas Pharma Inc Anticuerpos para el tratamiento de un cáncer que expresa la Claudina 6
US20140322723A1 (en) 2011-11-22 2014-10-30 President and Dellows of Harvard College Diabetes diagnosis through the detection of glycated proteins in urine
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
US20160024098A1 (en) 2013-03-15 2016-01-28 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
MX2016009653A (es) 2014-01-24 2017-03-27 Henry M Jackson Found Advancement Military Medicine Inc Anticuerpos contra glicoproteina f de virus hendra y nipah.
WO2016062323A1 (en) 2014-10-20 2016-04-28 Biontech Ag Methods and compositions for diagnosis and treatment of cancer
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
US10899829B2 (en) 2016-02-23 2021-01-26 Indiana University Research And Technology Corporation Emapii neutralizing antibody limits influenza A virus (IAV)-induced lung injury
WO2017213695A1 (en) 2016-06-07 2017-12-14 The Brigham And Women's Hospital, Inc. Compositions and methods relating to t peripheral helper cells in autoantibody-associated conditions
EP3625254B1 (en) 2017-07-31 2023-12-13 F. Hoffmann-La Roche AG Three-dimensional structure-based humanization method
CN119080931A (zh) 2018-06-04 2024-12-06 马萨诸塞州渤健公司 具有降低的效应功能的抗vla-4抗体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb

Also Published As

Publication number Publication date
MX9101046A (es) 1992-05-04
KR930702519A (ko) 1993-09-09
IE913177A1 (en) 1992-03-11
NZ239728A (en) 1995-07-26
GB9019812D0 (en) 1990-10-24
AU8505891A (en) 1992-03-30
AU654827B2 (en) 1994-11-24
CA2091335A1 (en) 1992-03-12
JPH06501152A (ja) 1994-02-10
ZA917170B (en) 1992-07-29
PT98944B (pt) 1999-02-26
WO1992004381A1 (en) 1992-03-19
EP0548190A1 (en) 1993-06-30

Similar Documents

Publication Publication Date Title
PT98944A (pt) Processo de preparacao de anticorpos alterados e de composicoes farmaceuticas para a prevencao e tratamento de infeccoes
BR1100850A (pt) Composto, processo para a preparação de um composto, e, composição farmacêutica
PT87259A (pt) Processo para a preparacao de composicoes farmaceuticas contendo 17-cetoesteroides apropriadas para o tratamento e a profilaxia de infeccoes retrovirais
BR9609701A (pt) Composição farmacéutica composto e processo para a preparação de compostos
BR9404114A (pt) Composição farmacêutica e seu processo de preparação
BR9611986A (pt) Compostos processo para a preparação dos mesmos composição farmcéutica e utilização dos compostos
BR9611198A (pt) Composto processo de preparação do mesmo e composição farmacêutica
BR9609780A (pt) Composto uso de um composto processo para o tratamento de condições composição farmacêutica processos para preparar uma composição farmacêutica e para preparar um composto
BR9600821A (pt) Composto formulação farmacêutica e processo para a preparação de um composto
BR9506473A (pt) Composto processo para a preparação de compostos utilização de um composto composição farmacêutica e processo para o tratamento de infecções anti-fúngicas
FI921875A7 (fi) Menetelmä lääkeaineina käyttökelpoisten bentsisotiatsoli- ja bentsisoksatsoli-3-karboksiamidien valmistamiseksi
BR9204361A (pt) Composto e processo para sua preparacao formulacao farmaceutica e intermediario
BR9604894A (pt) Derivado de acetamida processo para a preparação do mesmo e uma composição farmacêutica contendo o mesmo
BR9407869A (pt) Combinaçao composiçao farmacêutica e processo para o tratamento de osteoporose
BR9408148A (pt) Processo para tratamento de arritmia composto e formulação farmacêutica
BR9612135A (pt) Taxóides processo para sua preparação e composiç o farmacêutica
BR9612204A (pt) Composto uso do composto composição farmacêutica e processo para preparação do composto e para o tratamento de dor
BR9103036A (pt) Composto,formulacao farmaceutica e processo para a preparacao do composto
BR9502471A (pt) Composto de guanidina processo para preparar um composto de guanidina composição farmaceutica uso de um composto de guanidina método para o tratamento profilático ou terapêutico de doenças e processo para preparar uma composição farmacêutica
BR9101121A (pt) Composto,processo para sua preparacao,suas aplicacoes,e preparado farmaceutico
BR9206950A (pt) Composição farmacêutica e processo para sua preparação
BR9607346A (pt) Composto utilizaç o de um composto composiç o farmacéutica e processo para o tratamento de um mamifero e para e preparaç o de compostos
BR9301180A (pt) Processo para a preparacao de isocianatos e emprego
BR9506106A (pt) Composto processo para sua preparação medicamento e composição farmacêutica
PT97749A (pt) Processo para a preparacao de composicoes farmaceuticas contendo dsarn apropriadas para o diagnostico e o tratamento de hepatite viral

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19920407

FG3A Patent granted, date of granting

Effective date: 19981109

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20000531